Logo image of IPHA

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

NASDAQ:IPHA - Nasdaq - US45781K2042 - ADR

1.76  0 (0%)

Fundamental Rating

2

IPHA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. IPHA has a bad profitability rating. Also its financial health evaluation is rather negative. IPHA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IPHA had negative earnings in the past year.
IPHA had a negative operating cash flow in the past year.
IPHA had negative earnings in each of the past 5 years.
IPHA had negative operating cash flow in 4 of the past 5 years.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

With a decent Return On Assets value of -22.48%, IPHA is doing good in the industry, outperforming 74.87% of the companies in the same industry.
IPHA's Return On Equity of -118.25% is in line compared to the rest of the industry. IPHA outperforms 41.42% of its industry peers.
Industry RankSector Rank
ROA -22.48%
ROE -118.25%
ROIC N/A
ROA(3y)-17.27%
ROA(5y)-15.56%
ROE(3y)-57.01%
ROE(5y)-44.32%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of IPHA (88.00%) is better than 91.15% of its industry peers.
In the last couple of years the Gross Margin of IPHA has remained more or less at the same level.
IPHA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.32%
GM growth 5Y-0.15%
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IPHA has more shares outstanding
Compared to 5 years ago, IPHA has more shares outstanding
Compared to 1 year ago, IPHA has an improved debt to assets ratio.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -2.74, we must say that IPHA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.74, IPHA is in line with its industry, outperforming 48.50% of the companies in the same industry.
A Debt/Equity ratio of 2.73 is on the high side and indicates that IPHA has dependencies on debt financing.
IPHA has a Debt to Equity ratio of 2.73. This is amonst the worse of the industry: IPHA underperforms 83.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.73
Debt/FCF N/A
Altman-Z -2.74
ROIC/WACCN/A
WACC7.46%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 2.92 indicates that IPHA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.92, IPHA is doing worse than 66.90% of the companies in the same industry.
A Quick Ratio of 2.92 indicates that IPHA has no problem at all paying its short term obligations.
The Quick ratio of IPHA (2.92) is worse than 64.96% of its industry peers.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.92
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.50% over the past year.
IPHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -43.07%.
IPHA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.27% yearly.
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1531.56%
Revenue 1Y (TTM)-43.07%
Revenue growth 3Y-2.59%
Revenue growth 5Y-8.27%
Sales Q2Q%-76.54%

3.2 Future

IPHA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.16% yearly.
IPHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.99% yearly.
EPS Next Y28.59%
EPS Next 2Y39.4%
EPS Next 3Y36.16%
EPS Next 5YN/A
Revenue Next Year-18.02%
Revenue Next 2Y28.57%
Revenue Next 3Y34.8%
Revenue Next 5Y26.99%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IPHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

IPHA's earnings are expected to grow with 36.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.4%
EPS Next 3Y36.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (1/22/2025, 10:38:58 AM)

1.76

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners10.33%
Inst Owner Change0%
Ins Owners2.48%
Ins Owner ChangeN/A
Market Cap145.70M
Analysts78
Price Target5.46 (210.23%)
Short Float %0.16%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.48%
PT rev (3m)-3.41%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.75%
Revenue NY rev (3m)0.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.66
P/FCF N/A
P/OCF N/A
P/B 4.89
P/tB 4.91
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.31
BVpS0.36
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.48%
ROE -118.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88%
FCFM N/A
ROA(3y)-17.27%
ROA(5y)-15.56%
ROE(3y)-57.01%
ROE(5y)-44.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.32%
GM growth 5Y-0.15%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 2.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.84%
Cap/Sales 9.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.92
Altman-Z -2.74
F-Score2
WACC7.46%
ROIC/WACCN/A
Cap/Depr(3y)25.89%
Cap/Depr(5y)98.67%
Cap/Sales(3y)5.93%
Cap/Sales(5y)26.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1531.56%
EPS Next Y28.59%
EPS Next 2Y39.4%
EPS Next 3Y36.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-43.07%
Revenue growth 3Y-2.59%
Revenue growth 5Y-8.27%
Sales Q2Q%-76.54%
Revenue Next Year-18.02%
Revenue Next 2Y28.57%
Revenue Next 3Y34.8%
Revenue Next 5Y26.99%
EBIT growth 1Y-52.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.08%
EBIT Next 3Y46.8%
EBIT Next 5YN/A
FCF growth 1Y25.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.75%
OCF growth 3YN/A
OCF growth 5YN/A